Lerdelimumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lerdelimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target TGF beta 2
Clinical data
Legal status Development discontinued
Identifiers
CAS number 285985-06-0 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results.[2]

References[edit]

  1. ^ "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D (Adis International) 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006. 
  2. ^ "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.